Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Pediatric Venous Thromboembolism Clear all

Conditions: Deep Vein Thrombosis
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 1 Month to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Venous Thromboembolism
Interventions: Apixaban, Standard of Care; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 0 Days to 17 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 84
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more

Conditions: Thrombosis
Interventions: Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast; Procedure · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 18 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Little Rock, Arkansas • Aurora, Colorado • Kansas City, Missouri + 6 more

Conditions: Deep Vein Thrombosis, Venous Thromboembolism
Interventions: Edoxaban low dose, Edoxaban high dose; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 9 more

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Venous Thromboembolism (VTE)
Interventions: Enoxaparin; Drug
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 12 Years to 18 Years
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2035
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Venous Thromboembolism
Interventions: Apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orange, California • New Brunswick, New Jersey • Toledo, Ohio + 1 more

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more

Conditions: Venous Thromboembolism, Pediatrics, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Hematology Review; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 0 Years to 21 Years
Enrollment: 17,427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Venous Thromboembolism
Interventions: dalteparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 17
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Standard of Care; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Pediatric Venous Thromboembolism
Interventions: Labs drawn; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 6 Months to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Thromboembolism
Interventions: Apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 18
States / cities: Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more

Conditions: Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions: Edoxaban, Standard of Care; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Venous Thrombosis, Pediatrics
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more

Search by objective public record fields.

Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Pediatric Catheter-related Thrombosis Imaging Study

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Thrombosis Outcomes in Pediatric Venous Thromboembolism

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Risk Factors for Thrombosis in Children With Central Venous Lines

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis